Boehringer Ingelheim Vetmedica Gmbh

Gregor Meyers

Knut Elbers

Axel Lischewski

Martina Von Freyburg

Christiane Fetzer

Sabine Wirtz

Birke Andrea Tews

Eva-Maria Schuermann

Andreas Ege

Christiane Meyer

Jeffrey P Knittel

Craig Jones

Gregor Tremblay

The present invention relates i.a. to a CSFV (classical swine fever virus) comprising a substitution of proline to lysine at amino acid position 44 of the E2 protein and a substitution of threonine to aspartic acid at amino acid position 45 of the E2 protein. Further, the present invention provides an immunogenic composition comprising the CSFV of the present invention and the use of the immunogenic composition for reducing the incidence of or severity in an animal of one or more clinical signs associated with CSF. Moreover, the present invention provides a method of differentiating animals infected with CSFV from animals vaccinated with the immunogenic composition of the present invention.

Recombinant classical swine fever virus (CSFV) comprising substitution in the TAV epitope of the E2 protein

The present invention relates to recombinant attenuated pestiviruses, in particular to recombinant attenuated CSFV, BVDV, or BDV, wherein said recombinant attenuated pestivirus does not produce a dimeric Eglycoprotein. The present invention also relates to immunogenic compositions comprising such a pestivirus as well to a method of attenuating a pestivirus comprising the step of modifying the Eglycoprotein by a deletion, insertion or substitution wherein such modification results in a non dimeric Eglycoprotein.

Attenuated pestivirus

This invention relates to attenuated pestiviruses characterized in that their enzymatic activity residing in glycoprotein Eis inactivated, as well as methods of preparing, using and detecting these pestiviruses.

Attenuated pestiviruses

The invention belongs to the field of animal health and in particular Bovine Viral Diarrhea Virus (BVDV). The invention provides infectious BVDV clones and methods to produce said BVDV clones. The invention further relates to methods of attenuating said clones, attenuated BVDV clones and vaccines comprising said attenuated clones.

Infectious bovine viral diarrhea virus

This invention relates to attenuated pestiviruses characterised in that their enzymatic activity residing in glycoprotein Eis inactivated, methods of preparing, using and detecting these.

Method for inducing an immunological response in an animal

Attenuated pestiviruses, in particular attenuated BVDV, wherein at least one mutation is in the coding sequence for glycoprotein Eand at least another mutation in the coding sequence for Nwhich preferably leads to combined inactivation of the RNase activity residing in glycoprotein Ein addition to the inactivation of the (hypothesized) immunomodulating activity residing in N. Methods for attenuating pestiviruses such as BVDV, nucleic acids encoding the pestiviruses, in particular BVDV, compositions and vaccines comprising the attenuated pestiviruses, in particular BVDV, of the invention.

Vaccine comprising an attenuated pestivirus

Infectious bovine viral diarrhea virus clone

This invention relates to the use of specifically attenuated live BVD (bovine viral diarrhea) viruses for the preparation of a vaccine for use in the prevention and/or treatment of BVDV infections in breeding stocks of cattle, pregnant cows and for fetal protection in pregnant cows.

Growing community of inventors

Walddorfhaeslach, Germany

Gregor Meyers